Atea Pharmaceuticals Inc. (AVIR), a clinical-stage biopharmaceutical company developing oral antiviral therapeutics for serious viral diseases, has an upcoming clinical trial event next month that is worth keeping an eye on.
The first interim analysis of the company's SUNRISE-3 trial by an independent Data Safety Monitoring Board (DSMB) for safety and futility is expected this March.
SUNRISE-3 is a global, registrational phase III trial evaluating the antiviral drug candidate Bemnifosbuvir against placebo administered concurrently with locally available standard of care (SOC) for the treatment of COVID-19.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.